Aldosterone synthase gene polymorphism in alimentary obesity, metabolic syndrome components, some secondary forms of arterial hypertension, pathology of the adrenals glands core (literature review)

S.N. Koval, D.K. Miloslavsky, I.A. Snegurskaya, O.V. Mysnichenko, M.Yu. Penkova


Hormonal factors of adrenal origin belong to the pathophysiological mechanisms of the formation and progression of arterial hypertension (AH) and should be consi­dered while developing differentiated approaches to the treatment and prevention of hypertensive states, their primary, secondary and resistant forms. The first thing we should point up is aldosterone (AL), enzyme aldosterone synthase (AS), which takes a direct part in the formation of this hormone, as well as gene polymorphisms of AS, which have not only molecular genetic, but also differential diagnostic and therapeutic significance for secondary forms of arterial hypertension, abdominal obesity (AO), metabolic syndrome (MS), adrenal pathology and other endocrine disorders. AL is a steroid (mineralocorticoid) hormone of the adrenal cortex, which is synthesized from cholesterol (CH), mainly in the glomerular zone of the adrenal glands, is released under the action of angiotensin II (A II) and potassium ions (K+). AL acti­vity is mediated through the corresponding mineralocorticoid receptors (MKR). The particular importance in AH and MS development belongs to AL activation and MKR density in adipocytes, this phenomenon is accompanied by increased expression of pro-inflammatory cytokines, leptin, an adipogenic effect, and the inhibition of MCR activity is accompanied by increased production of adiponectin, which is more pronounced in patients with AH. Aldosterone synthase, a mitochondrial human enzyme encoded by the CYP11B2 gene (cytochrome P450, family 11, subfamily B, polypeptide 2) is located on the 8th chromosome. AS belongs to the superfamily of cytochrome P450 and regulates the synthesis of AL hormone. The CYP11B2 gene encodes the key enzyme for the synthesis of AL 18-hydroxylase. In scientific papers, single nucleotide polymorphism (SNP) of AS gene is often studied, such as 5312T, Intron 2, Lys-173/Arg; T-344C, 3097 C/A. 227 SNP of the AS gene were identified in different populations. Europeans, Asians, Africans and North Americans were among them and were genotyped by CYP11B2. To date, there is ample evidence that fatty tissue (FT), apart from a source of energy, is an active endocrine organ that plays a key role in maintaining homeostasis and participating in the pathogenesis of a number of diseases. Its excess is accompanied by hyperactivation of tissue renin-angiotensin-aldosterone system (RAAS), strengthening of local and systemic synthesis of AL and the emergence of secondary aldosteronism. AL, in its turn, has a direct effect on FT due to increased MKR density expressed on adipocytes surface, leading to acceleration in the maturation of the latter and a further increase in FT. Getting into the systemic blood circulation and effecting other organs, the excess AL promotes the development of insulin resistance, atherosclerosis, the progression of systemic inflammatory reactions. MKR activation in FT plays not only the key role in sodium reabsorption by kidneys and the control of BP, but also in the differentiation of preadipocytes into mature adipocytes in FT, induction of inflammation and hyperproduction of cytokines — tumor necrotic factor alpha (TNF-α), monocyte chemotactic protein (MCP-1) and interleukin 6 (IL-6) in the white FT, a decrease in the thermogenic activity and trans­cription of the uncoupling protein-1 (UCP-1) in brown FT. MCR hyperactivation was detected in mice with AO (obese db/db mice), associated with increased BMI in humans and contributes to the development of IR and associated with AO cardiovascular diseases. The gene polymorphism of AS may be a marker of aggravated pregnancy, the presence of gestational hypertension or pre-eclampsia. Some studies found that AS gene polymorphism can affect plasma glucose levels. AS gene polymorphism was not associated with the progression of diabetic nephropathy (DN), but is associated with AH in persons with type 2 diabetes mellitus. National authors conclude about the association of the genotype TT(-344) of the gene CYP11B2 with the risk of MS among residents of the North-West region of Russia. The carrier of 344T allele of AS gene in patients with AO was associated with an increased risk of hypertension development. The features of AS gene polymorphism and blood levels in acromegaly have been stu­died, and the allelic polymorphism of AS and chymase genes (CMA) has been analyzed to identify the possible association of alleles of these genes with secondary hypertension and hyperaldosteronism in Russians. The congenital defects of the enzymatic activity of AS are of undoubted interest. AS gene is a promising candidate gene in the European and Asian populations for a number of secondary forms of hypertension, MS, diabetes mellitus, abdominal obesity, renal pathology, diabe­tic nephropathy, gestational hypertension. Genotyping of AS gene polymorphisms can be useful in differential diagnostic in patients with secondary forms of arterial hypertension, hypertension with low plasma renin activity, renovascular and resistant hypertension, adrenal tumors, primary and secondary hyperaldosteronism, aldosteromas, imaginary excess of mi­neralcorticoids syndrome, congenital hyperplasia of adrenal cortex. The advantages and disadvantages of the therapeutic use of MCR antagonists and the prospects for the administration of aldosterone synthase inhibitors among various categories of patients are considered. Carrying out the genotyping of patients by the CYP11B2 gene before therapy starting will allow take into account the genetic factors of sensitivity to drug in patients with the phenomenon of arterial hypertension and endocrine disorders. New AS inhibitors will not only effectively reduce blood pressure, but also will be able to prevent the development of adverse humoral and hormonal changes, what will prolong the life of patients and will help to reduce the level of total mortality from this pathology.


levels and gene polymorphism of aldosterone synthase; obesity; metabolic syndrome; secondary arterial hypertension; hyperaldosteronism; aldosterone synthase inhibitors; review


Vecchiola A, Lagos CF, Carvajal CA, Baudrand R, Fardella CE. Aldosterone Production and Signaling Dysregulation in Obesity. Curr Hypertens Rep. 2016;18(3):20. doi: 10.1007/s11906-016-0626-9.

Jones ES, David Spence J, Mcintyre AD, et al. High Frequency of Variants of Candidate Genes in Black Africans with Low Renin-Resistant Hypertension. Am J Hypertens. 2017;30(5):478-83. doi: 10.1093/ajh/hpw167.

Alvarez-Madrazo S, Connell JM, Freel EM. Role of genetic variation in regulation of aldosterone biosynthesis. Endocr Dev. 2011;20:106-15. doi: 10.1159/000321229.

Ruilope LM. Aldosterone, hypertension, and cardiovascular disease: an endless story. Hypertension. 2008 Aug;52(2):207-8. doi: 10.1161/HYPERTENSIONAHA.108.111211.

Sun J, Zhao M, Miao S, Xi B. Polymorphisms of three genes (ACE, AGT and CYP11B2) in the renin-angiotensin-aldosterone system are not associated with blood pressure salt sensitivity: A systematic meta-analysis. Blood Press. 2016;25(2):117-22. doi: 10.3109/08037051.2015.1110923.

Colussi G, Catena C, Lapenna R. et al. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 2007 Sep; 30(9): 2349-54. doi:10.2337/dc07-0525.

Cooper SA, Whaley-Connell A, Habibi J. et al. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol. 2007 Oct;293(4):H2009-23. doi: 10.1152/ajpheart.00522.2007.

Brown NJ. Aldosterone and vascular inflammation. Hypertension. 2008 Feb;51(2):161-7. doi: 10.1161/HYPERTENSIONAHA.107.095489.

Gluba A, Banach M, Mikhailidis DP, Rysz J. Genetic determinants of cardiovascular disease: the renin-angiotensin-aldosterone system, paraoxonases, endothelin-1, nitric oxide synthase and adrenergic receptors. In Vivo. 2009;23(5):797-812. PMID: 19779116.

Krug AW, Ehrhart-Bornstein M. Aldosterone and metabolic syndrome. Is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertens. 2008;51(5):1252-60. doi: 10.1161/HYPERTENSIONAHA.107.109439. 

Kidambi S, Kotchen JM, Grim CE, et al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension. 2007 Mar;49(3):704-11. doi: 10.1161/01.HYP.0000253258.36141.c7.

Kim YR, Kim SH, Kang SH, Kim HJ, Kong MH, Hong SH. Association of CYP11B2 polymorphisms with metabolic syndrome patients. Biomed Re. 2014 Sep;2(5):749-54. doi: 10.3892/br.2014.316.

Pavlova OS, Ogurtsova SE, Gorbat TV. et al. Polygenic association of the renin-angiotensinaldosterone system polymorphisms in essential arterial hypertension. Arterial’naya Gipertenziya. 2016;22(3):253-62. doi: 10.18705/1607-419X-2016-22-3-253-262. (in Russian).

Cheng X, Xu G. Association between aldosterone synthase CYP11B2 polymorphism and essential hypertension in Chinese: a meta-analysis. Kidney Blood Press Res. 2009;32(2):128-40. doi: 10.1159/000215738.

Iwai N, Kajimoto K, Tomoike H, Takashima N. Polymorphism of CYP11B2 determines salt sensitivity in Japanese. Hypertension. 2007;49(4):825-31. doi: 10.1161/01.HYP.0000258796.52134.26.

Bellili NM, Foucan L, Fumeron F. et al. Associations of the -344 T>C and the 3097 G>A polymorphisms of CYP11B2 gene with hypertension, type 2 diabetes, and metabolic syndrome in a French population. Am J Hypertens. 2010 Jun;23(6):660-7. doi: 10.1038/ajh.2010.44.

MacKenzie SM, Davies E, Alvarez-Madrazo S. Analysis of the Aldosterone Synthase (CYP11B2) and 11β-Hydroxylase (CYP11B1) Genes. Methods Mol Biol. 2017;1527:139-150. doi: 10.1007/978-1-4939-6625-7-11.

Freel EM, Ingram M, Friel EC, et al. Phenotypic consequences of variation across the aldosterone synthase and 11-beta hydroxylase locus in a hypertensive cohort: data from the MRC BRIGHT Study. Clin Endocrinol (Oxf). 2007;67(6):832-8. doi: 10.1111/j.1365-2265.2007.02971.x.

Zhang GX, Wang BJ, Ouyang JZ, et al. Polymorphisms in CYP11B2 and CYP11B1 genes associated with primary hyperaldosteronism. Hypertens Res. 2010 May;33(5):478-84. doi: 10.1038/hr.2010.21.

Ma I, Ulitina AS, Ionin VA. et al. С(-344)Т polymorphism of aldosterone synthase gene, risk of metabolic syndrome, and atrial fibrillation risk for inhabitants of the Northwest regions of Russia. Uchenyie zapiski Sankt-Peterburgskogo gosudarstvennogo meditsinskogo universiteta imeni akademika I.P. Pavlova. 2016;23(2):46-49. (in Russian).

Ramachandran V, Ismail P, Stanslas J, Shamsudin N. Analysis of renin-angiotensin aldosterone system gene polymorphisms in Malaysian essential hypertensive and type 2 diabetic subjects. Cardiovasc Diabetol. 2009 Feb 25;8:11. doi: 10.1186/1475-2840-8-11.

Pan X, Liu Y, Zhang Y, Zhang X, Xu Q, Tong W. Interaction of the C-344T polymorphism of CYP11b2 gene with body mass index and waist circumference affecting diastolic blood pressure in Chinese Mongolian population. Blood Press. 2010 Dec;19(6):373-9. doi: 10.3109/08037051.2010.495859.

Casiglia E, Tikhonoff V, Schiavon L. [et al.] Skinfold thickness and blood pressure across C-344T polymorphism of CYP11B2 gene. J Hypertens. 2007;25(9):1828-33. doi: 10.1097/HJH.0b013e32826308a0.

Dinh Cat AN, Friederich-Persson M, White A, Touyz RM. Adipocytes, aldosterone and obesity-related hypertension. J Mol Endocrinol. 2016 Jul;57(1):F7-F21. doi: 10.1530/JME-16-0025.

Kawarazaki W, Fujita T. The Role of Aldosterone in Obesity-Related Hypertension. Am J Hypertens. 2016 Apr;29(4):415-23. doi: 10.1093/ajh/hpw003.

Vatutin NT, Shevelyok AN, Degtiarova AE. Aldosterone and obesity: where to look for the key to therapy? Archive of Internal Medicine. 2016;30(4):21-29. doi: 10.20514/2226-6704-2016-6-4-21-29. (in Russian).

Borghi F, Sevá-Pessôa B, Grassi-Kassisse DM. The adipose tissue and the involvement of the renin-angiotensin-aldosterone system in cardiometabolic syndrome. Cell Tissue Res. 2016;366(3):543-8. doi: 10.1007/s00441-016-2515-6.

Garg R, Adler GK. Aldosterone and the Mineralocorticoid Receptor: Risk Factors for Cardiometabolic Disorders. Curr Hypertens Rep. 2015;17(7):52. doi: 10.1007/s11906-015-0567-8.

Schütten MT, Houben AJ, de Leeuw PW, Stehouwer CD. The Link Between Adipose Tissue Renin-Angiotensin-Aldosterone System Signaling and Obesity-Associated Hypertension. Physiology (Bethesda). 2017;32(3):197-209. doi: 10.1152/physiol.00037.2016.

Xing Y, Cohen A, Rothblat G, et al. Aldosterone production in human adrenocortical cells is stimulated by high-density lipoprotein 2 (HDL2) through increased expression of aldosterone synthase (CYP11B2). Endocrinology. 2011;152(3):751-63. doi: 10.1210/en.2010-1049.

Matsuda M, Shimomura I. Roles of oxidative stress, adiponectin, and nuclear hormone receptors in obesity-associated insulin resistance and cardiovascular risk. Horm Mol Biol Clin Investig. 2014;19(2):75-88. doi: 10.1515/hmbci-2014-0001.

Huby AC, Antonova G, Groenendyk J, et al. Adipocyte-Derived Hormone Leptin Is a Direct Regulator of Aldosterone Secretion, Which Promotes Endothelial Dysfunction and Cardiac Fibrosis. Circulation. 2015;132(22):2134-45. doi: 10.1161/CIRCULATIONAHA.115.018226.

Hofmann A, Peitzsch M, Brunssen C, et al. Elevated Steroid Hormone Production in the db/db Mouse Model of Obesity and Type 2 Diabetes. Horm Metab Res. 2017;49(1):43-49. doi: 10.1055/s-0042-116157.

Yamashiro T, Kuge H, Zhang J, Honke K. Calcineurin mediates the angiotensin II-induced aldosterone synthesis in the adrenal glands by up-regulation of transcription of the CYP11B2 gene. J Biochem. 2010;148(1):115-23. doi: 10.1093/jb/mvq037.

Briones AM, Nguyen Dinh Cat A, Callera GE. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension. 2012;59(5):1069-78. doi: 10.1161/HYPERTENSIONAHA.111.190223.

Rios FJ, Neves KB, Nguyen Dinh Cat A, et al. Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes. J Pharmacol Exp Ther. 2015;353(1):27-34. doi:10.1124/jpet.114.221002.

Zhu L, Ke Y, Shao D. et al. PPARγ co-activator-1α co-activates steroidogenic factor 1 to stimulate the synthesis of luteinizing hormone and aldosterone. Biochem J. 2010;432(3):473-83. doi: 10.1042/BJ20100460.

Lastra G, Sowers JR. Obesity and cardiovascular disease: role of adipose tissue, inflammation, and the renin-angiotensin-aldosterone system. Horm Mol Biol Clin Investig. 2013;15(2):49-57. doi: 10.1515/hmbci-2013-0025.

Brovin DL, Bazhenova EA, Popov RE. Distribution of genotypes and alleles of the aldosterone-synthase gene in patients with abdominal obesity. Uchenyie zapiski Sankt-Peterburgskogo gosudarstvennogo meditsinskogo universiteta imeni akademika I.P. Pavlova. 2015;22(2) :20-23. (in Russian).

Li XM, Ling Y, Lu DR, et al. Association of the aldosterone synthase gene -344T>C polymorphism with essential hypertension and glucose homeostasis: a case-control study in a Han Chinese population. Clin Exp Pharmacol Physiol. 2011;38(9):598-604. doi: 10.1111/j.1440-1681.2011.05555.x.

Ko GJ, Kang YS, Lee MH, Song HK, Kim HK, Cha DR. Polymorphism of the aldosterone synthase gene is not associated with progression of diabetic nephropathy, but associated with hypertension in type 2 diabetic patients. Nephrology (Carlton). 2008 Dec;13(6):492-9. doi: 10.1111/j.1440-1797.2008.01005.x.

Purkait P, Suthar PC; Purohit VK; Naidu JM; Sarkar BN. Renin Angiotensin Aldosterone System gene polymorphisms in Type 2 Diabetic patients among the Mewari population of Rajasthan. Int J Biol Med Res. 2013;4(2):3128-34.

Purkait P, Raychodhury P, Bandhyopadhya S, Naidu JM, Sarkar BN Analysis of Aldosterone Synthase Gene Promoter (-344 C >T) Polymorphism in Indian Diabetic Nephropathy Patients. J Diabetes Metab. 2013;4:271. doi: 10.4172/2155-6156.1000271.

Ramírez-Salazar M, Romero-Gutiérrez G, Zaina S, Malacara JM, Kornhauser C, Pérez-Luque E. Relationship of aldosterone synthase gene (C-344T) and mineralocorticoid receptor (S810L) polymorphisms with gestational hypertension. J Hum Hypertens. 2011;25(5):320-6. doi: 10.1038/jhh.2010.58. 

Verlohren S, Muller DN, Luft FC, Dechend R. Immunology in hypertension, preeclampsia, and target-organ damage. Hypertension. 2009;54:439-46. doi: 10.1161/HYPERTENSIONAHA.108.120253.

Radkov OV, Kalinkin MN, Zavarin VV. Impact of the polymorphism –344T/C of aldosteron synthase gene on components of renin-angiotensin-aldosterone system and heart rate variability in pregnant women with preeclampsia. The Siberian Scientific Medical Journal. 2012;32(3):102-106. (in Russian).

Bogacz A, Bartkowiak-Wieczorek J, Procyk D. et al. Analysis of the gene polymorphism of aldosterone synthase (CYP11B2) and atrial natriuretic peptide (ANP) in women with preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2016;197:11-5. doi: 10.1016/j.ejogrb.2015.11.012. 

de Vasconcelos D, Izidoro-Toledo TC, Sandrim VC, Tanus-Santos JE, Palei AC, Cavalli RC. Aldosterone synthase gene polymorphism is not associated with gestational hypertension or preeclampsia. Clin Chim Acta. 2009;400(1-2):139-41. doi: 10.1016/j.cca.2008.11.002. 

Chikhladze NM, Samedova KhF, Sudomoina MA, et al. Comparative genetic analysis of different forms of low-renin arterial hypertension. Mol Biol (Mosk). 2008;42(4):588-98. (in Russian). PMID: 18856058.

Chikhladze NM, Samedova KhF, Sudomoina MA. et al. Contribution of CYP11B2, REN and AGT genes in genetic predisposition to arterial hypertension associated with hyperaldosteronism. Kardiologiia. 2008;48(1):37-42. PMID: 18260994 (in Russian).

Samedova HF. Research of genetic predisposition to the lowrenin forms of arterial hypertension with hyperaldosteronism, in comparison with the features of clinical features of disease. Avt. dissertatsii na soiskanie uchenoy stepeni kandidata meditsinskih nauk. Moscow, 2009:27 (in Russian).

Mulatero P, Veglio F, Maffei P, et al. CYP11B2 -344T/C gene polymorphism and blood pressure in patients with acromegaly. J Clin Endocrinol Metab. 2006;91(12):5008-12. doi: 10.1210/jc.2006-0049.

Kalita OV, Parfenov MG, Chihladze NM, et al. Analysis of allelnle genes polimorphism of aldosteronsintase in patients with arterial hypertension in russians. Available from: (in Russian)

Rossi G, Pessina AC, Heagerthy AM. Primary aldosteronism an update on screening diagnosis and treatment. J Hypertens. 2008 Apr;26(4):613-21. doi: 10.1097/HJH.0b013e3282f4b3e6.

Matrozova J, Steichen O, Amar L. et al. Fasting plasma glucose and serum lipids in patients with primary aldosteronism. A controlled cross-sectional study. Hypertens. 2009;53:605-612.

Alimukhamedova GA, Khalimova ZYu, Ismailov SI. Genetic aspects of adrenal incidentalomas. Mezhdunarodnyi Endokrinologicheskii Zhurnal. 2010;5(29):23-28. (in Russian).

Vorohobina NV, Serebryakova IP, Galahova RK, Balandina KA. Arterial hypertension in patients with adrenal pathology. Lechaschiy vrach. 2017;3:21-24. (in Russian).

Kalinchenko NYu, Zubkova NA, Tyulpakov AN. Molecular genetic verification of isolated mineralocorticoid deficiency due to aldosterone synthase deficiency. Problemyi endokrinologii. 2009;1(55):28-30 (in Russian).

Li N, Li J, Ding Y. et al. Novel mutations in the CYP11B2 gene causing aldosterone synthase deficiency. Mol Med Rep. 2016;13(4):3127-32. doi: 10.3892/mmr.2016.4906.

Xu L, Xia W, Wu X. et al. Chimeric CYP11B2/CYP11B1 causing 11β-hydroxylase deficiency in Chinese patients with congenital adrenal hyperplasia. Steroids. 2015;101:51-5. doi: 10.1016/j.steroids.2015.06.002.

Tykhonova SA, Piskovats'ka VP. Prognostic meaningfulness of polymorphic allelic variants of aldosterone synthase gene in patients with arterial hypertension. Odes’kij medičnij žurnal. 2015;5(151):81-85. (in Ukrainian)

Li Y, Yang P, Wu SL, et al. Effect of CYP11B2 gene -344T/C polymorphism on renin-angiotensin-aldosterone system activity and blood pressure response to hydrochlorothiazide. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2012 Feb;29(1):68-71. doi: 10.3760/cma.j.issn.1003-9406.2012.01.017. (in Chinese)

Karashima S, Yoneda T, Kometani M. et al. Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism. Hypertens Res. 2016;39(3):133-7. doi: 10.1038/hr.2015.129.

Morales E, Gutiérrez E, Caro J. et al. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria. Nefrologia. 2015;35(6):554-61. doi: 10.1016/j.nefro.2015.09.008.

Armani A, Cinti F, Marzolla V, et al. Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice. FASEB J. 2014;28(8):3745-57. doi: 10.1096/fj.13-245415.

Caprio M, Antelmi A, Chetrite G, Muscat A, Mammi C, Marzolla V, Fabbri A, Zennaro MC, Fève B. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology. 2011;152(1):113-25. doi: 10.1210/en.2010-0674.

Hofmann A, Brunssen C, Peitzsch M. et al. The Aldosterone Synthase Inhibitor FAD286 is Suitable for Lowering Aldosterone Levels in ZDF Rats but not in db/db Mice. Horm Metab Res. 2017;49(6):466-471. doi: 10.1055/s-0043-101821.

Abdel-Magid AF. Aldosterone synthase inhibitors: targeting chronic kidney disease and diabetic nephropathy. ACS Med Chem Lett. 2013;4(2):157-8. doi: 10.1021/ml4000172.

Andersen K, Hartman D, Peppard T. et al. The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study. J Clin Hypertens (Greenwich). 2012;14(9):580-7. doi: 10.1111/j.1751-7176.2012.00667.x.

Hu Q, Yin L, Hartmann RW. Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases. J Med Chem. 2014;57(12):5011-22. doi: 10.1021/jm401430e.

Ménard J, Rigel DF, Watson C. et al. Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects. J Transl Med. 2014;12:340. doi: 10.1186/s12967-014-0340-9.



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© "Publishing House "Zaslavsky", 1997-2017


 Яндекс.МетрикаSeo анализ сайта Рейтинг